Evotec Spin-Off Eyes Early Clinical POC With Immune Tolerance Platform
This article was originally published in Scrip
Evotec AG of Germany has spun out a drug discovery company called Topas Therapeutics GmbH. It is being launched with a €14m series A financing round led by VC firm Epidarex Capital, of which Eli Lilly is an investor. The round also included EMBL Ventures, Gimv and Evotec.
Register for our free email digests: